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Abstract
Background: Atypical fibroxanthoma (AFX) histologically mimics high-grade sarcoma in the skin,
although it follows a benign clinical course. AFX occurs in the sun-exposed skin and for this reason,
an association with ultraviolet light has long been suspected. Bax and Gadd45 are p53 effector
proteins. Bax is a programmed cell death protein and belongs to the Bcl-2 family. Gadd45 is a
multifunctional DNA damage-inducible gene associated with the process of DNA damage.
Methods: Immunohistochemical expression of Bax was analyzed in 7 cases of AFX, and in 7 cases
of benign fibrous histiocytoma (BFH) used as a comparison. The expression pattern of Bax was
compared to previously reported p53 and Gadd45 expressions in a correspondent series. Mutation
of the Gadd45 gene at exon 4 was also analyzed in AFX.
Results: AFX and BFH showed immunoreactivities respectively for Bax (3/7, 0/7), Gadd45 (4/7, 1/
7) and p53 (2/7, 0/7). There was no exact correlation between p53 expression and Bax or Gadd45
expression. However, the pattern of expression between Bax and Gadd45 was also the same, with
the exception of one case. No mutation of the Gadd45 gene at exon 4 was observed in a series of
6 AFX cases where DNA was available (0/6).
Conclusion: These results suggest a possible association between Bax and Gadd45 in AFX, and
may refute any possibility of dysfunction of Gadd45 in terms of gene mutation, at least at exon 4
of the Gadd45 gene.
Background
Atypical fibroxanthoma (AFX) is a nodular ulcerative
lesion arising from the sun-exposed skin of the head and
neck, typically in the elderly [1,2]. Solar elastosis associ-
ated with UV-radiation has been commonly observed in
AFX cases [3]. Association between AFX and ultraviolet
(UV) radiation has been suspected. On the other hand, in
its less common forms with weakened association with
UV, AFX occurs on the extremities and the trunk [1,2]. AFX
is composed of spindle, plump, epithelioid and bizarre
cells, in various proportions, arranged in haphazard,
vaguely fascicular or storiform patterns. These histological
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features of AFX mimic those of high-grade sarcoma, such
as malignant fibrous histiocytoma or leiomyosarcoma
[2,4], which occurs deep within soft tissue.
The tumor-suppressor protein p53 is a transcriptional
activator which is involved in cell-cycle control, DNA
repair, apoptosis and chromosome/genome instability.
UV-induced p53 gene mutations occurring at dipyrimi-
dine sites have been demonstrated in AFX, suggesting a
central role for UV radiation in the pathogenesis of AFX
[5]. These p53 functions are mediated through its tran-
scriptional target (effector) proteins, such as Bax and
Gadd45 (growth arrest and DNA damage inducible) [6].
Bax is a pro-PCD (programmed cell death) protein and
belongs to the Bcl-2 family [7]. Furthermore, Bax is impor-
tant for p53-dependent PCD [8,9]. Gadd45 is a DNA
damage-responsive gene that is rapidly induced by agents
that cause DNA damage, including UV radiation. Gadd45
is a multifunctional protein which has roles to play in cell-
cycle arrest, genomic stability, nucleotide excision repair,
chromatin accessibility and apoptosis [10-12]. Although
mutation of the Gadd45 gene is not common in tumors
[13,14], some research has been reported showing that
point mutations of Gadd45 gene at exon 4 were found in
13.6% of pancreatic cancer cases, suggesting the possibil-
ity that Gadd45 is dysfunctional in this tumor type [15].
We have previously reported the expression of Gadd45 in
a series of AFX without mutation analysis [16].
In the current study, we evaluate the immunoexpression
pattern of Bax in AFX. The existence of a mutation at exon
4 of the Gadd45 gene is also examined in order to refute
the possibility of any dysfunction of Gadd45, regardless of
its expression. We also discuss the correlation of immu-
noexpression among Bax, Gadd45 and p53 in the corre-
spondent cases. We use benign fibrous histiocytoma
(BHF), or dermatofibroma, as the comparison. BHF is a
benign fibrohistiocytic tumor composed of a mixture of
fibroblastic and histiocytic cells, most commonly seen in
the dermis and superficial subcutis [2].
Methods
Cases of AFX and BFH
Seven cases of AFX and seven cases of BFH as a compari-
son were collected from the histopathological files at the
Department of Anatomic Pathology, Kyushu University.
The BFH cases were collected at random. These cases of
AFX and BFH for Bax immunohistochemical analysis were
exactly the same cases as those used for p53 immunohis-
tochemical analysis in a previous report [17]. As for
Gadd45 immunohistochemical analysis, although the
cases were also the same as those used in our previous
study [16], a few of those earlier cases were omitted from
the current study, due to a lack of sufficient available
materials. In the current study, an association among the
expression of Bax, Gadd45 and p53 was compared in the
correspondent cases. The research was performed under
the approval of the Department of Anatomic Pathology
and the Department of Orthopaedic Surgery, Kyushu Uni-
versity. Patients were informed that resected tumor sam-
ples might be used for research analysis. The explanation
and the consensus were recorded on their medical charts.
The research was performed ethically, in compliance with
the Helsinki Declaration. In addition, the study was per-
formed anonymously in order to protect the identity of
the patients.
Immunohistochemical staining
Four-micron-thick histological sections of 10% formalin-
fixed and paraffin-embedded materials were deparaffin-
ized. After dehydration, endogenous peroxidase was
blocked by methanol containing 0.3% H2O2 for 30 min.
The sections were incubated with the primary antibody at
4°C overnight, followed by reaction with the streptavidin-
biotin complex method using an SAB-PO kit (Nichirei,
Tokyo, Japan). The sections were then finally reacted in a
3,3'diaminobenzidine, peroxytrichloride substrate solu-
tion and counterstained with hematoxylin or methyl
green. The antibody used in this study was gout polyclo-
nal antibody for Bax. Its dilution was 1:200 for anti-Bax
(P-19, Santa Cruz Biotechnology, Santa Cruz, CA). Speci-
mens were pretreated by heating in a microwave oven.
Immunoexpression results of Gadd45 (H165-X; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) [16] and p53
(PAb1801, Oncogene Research Products, San Diego, CA,
USA) [17] have been reported previously.
Formalin-fixed, paraffin-embedded tissue DNA extraction
DNA was extracted from a paraffin-embedded tissue sec-
tion as follows. Paraffin was removed with xylene, and
then the sample was washed twice with 100% ethanol and
subsequently dried. The tissue was suspended in digestion
buffer (100 mM sodium chloride, 10 mM Tris-hydrochlo-
ric acid, 25 mM EDTA, and 0.5% sodium dodecyl sulfate)
containing 10 mg proteinase K, before being incubated
overnight at 55°C. DNA, precipitated by adding twice the
volume of ethanol, was washed with 70% ethanol, before
being resuspended in TE buffer (10 mM Tris, 1 nM EDTA)
for storage at 4°C.
Polymerase chain reaction (PCR) and direct sequencing
A fragment of the Gadd45 gene at exon 4 was amplified by
PCR. The PCR primers used were 5'-TTTGTTTCCAGAATC-
CACATTC-3' (sense) and 5'-AAAACTTCAGT-
GCAATTTGG-3' (antisense). The PCR was run in 35 cycles
consisting of denaturation at 94°C for 1 min, annealing at
56°C for 45 sec, and extension at 72°C for 1 min. The
amplified PCR fragments were purified by Purification
System (BenevBio, Mission Viejo, CA). After the purifica-BMC Dermatology 2009, 9:1 http://www.biomedcentral.com/1471-5945/9/1
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tion, direct sequencing was carried out by the dideoxy
chain termination method using a Perkin Elmer ABI 3100
sequence analyzer (Applied Biosystems, Foster City, CA).
Antisense primer was used as the sequencing primer.
Assessment of immunoreactivity
Neoplastic cells that showed distinct nuclear or cytoplas-
mic staining, depending on the antibodies used, were
considered positive. Positive cut-off values for each type of
immunoexpression were adopted as follows; more than
10% for Bax in the nuclei [18], more than 25% for
Gadd45 in the cytoplasm [19], and more than 5% for p53
in the nuclei [17].
Statistical analysis
The data regarding immunohistochemistry were analyzed
using Fisher's exact test. A P value of less than 0.05 was
considered to indicate statistical significance.
Results
Clinical features
The clinical features are listed in Table 1. The average ages
(in years) of patients with these lesions were as follows;
AFX (n = 7; average age, 66.0; range, 46–84) and BFH (n
= 7; average age, 29.6; range, 18–38). AFX showed a male-
female predominance of 6 to 1. BFH occurred in 2 males
and 5 females. AFX occurred on the sun-exposed skin of
the scalp (1 case), face (1 case), auricle (2 cases) and finger
(2 cases) in 6 cases, while it occurred on the leg in the
other one case. BFH occurred at various sites of the trunk
and the extremities (chest wall, 1 case; back, 1 case; thighs,
2 cases; forearm, 1 case; and legs, 2 cases) but none of
these lesions occurred on sun-exposed parts. No recur-
rence was observed among these 7 AFX and 7 BFH cases.
Histological features
AFX is a nodular ulcerative lesion composed of various
proportions of a mixture of spindle and pleomorphic
cells, arranged in a haphazard or disorderly pattern (Fig-
ure 1). The BFH cases were located in the dermis or the
superficial subcutis. BFH consisted of fibroblastic cells
and histiocytic cells arranged in short interlacing fascicles
or a vague storiform pattern. The tumor cells of BFH dem-
onstrated no pleomorphism.
Immunohistochemical findings
Immunohistochemical data are shown in Tables 1 and 2.
The immunohistochemical data of Gadd45 [16] and p53
[17] in AFX and BFH have been reported previously. AFX
showed positive expression of Bax in 3 cases (3/7; 43%),
of Gadd45 in 4 cases (4/7; 57%) and of p53 in 3 cases (2/
7; 29%) among a total of 7 cases. As for BFH, Bax (07;
0%), Gadd45 (1/7; 14%) and p53 (0/7; 0%) expressions
were virtually absent in the 7 BFH cases, with the excep-
tion of 1 case that showed Gadd45 expression (1/7; 14%).
The expression pattern of Bax and Gadd45 was also the
same, with 3 cases positive for both and 3 cases negative
for both, the one exception being one AFX case which was
positive for Gadd45, but negative for Bax. Therefore, it
seemed that there was a correlation in the expression
between Bax and Gadd45 in the AFX cases. On the other
hand, there seemed to be no correlation between p53
expression, and the expression of Bax or Gadd45. The fre-
quency of Bax in AFX (3/7; 43%) was statistically higher
than that in BFH (0/7; 0%) (p < 0.05), whereas there was
Table 1: Clinical and immunohistochemical features of AFX and BFH
Lesion Age/Sex/Location Bax Gadd45* Gadd45 mutation at exon 4 p53*
A3 AFX 82/M/Scalp - - NA -
A7 AFX 84/M/Face - + - -
A10 AFX 65/M/Auricle - - - +
A14 AFX 71/M/Auricle + + - +
A16 AFX 50/M/Finger - - - -
A17 AFX 46/M/Finger + + - -
A19 AFX 64/F/Leg + + - -
B8 BFH 18/F/Thigh - - NA -
B9 BFH 38/F/Back - - NA -
B12 BFH 32/M/Thigh - - NA -
B13 BFH 35/F/Leg - + NA -
B16 BFH 30/F/Chest wall - - NA -
B17 BFH 23/M/Forearm - - NA -
B21 BFH 31/F/Leg - - NA -
AFX, atypical fibroxanthoma; BFH, benign fibrous histiocytoma (BFHs were selected at random from our histological files); *, data were reported 
previously; NA, not assessed.BMC Dermatology 2009, 9:1 http://www.biomedcentral.com/1471-5945/9/1
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no significant difference in Gadd45 and p53 expression
between the AFX and BFH cases (p > 0.05).
Mutation of Gadd45 at exon 4
Mutation of the Gadd45 gene at exon 4 was not observed
in the series of 6 AFX cases where DNA was available (0/
6; 0%), regardless of Gadd45 immunoexpression.
Discussion
AFX typically occurs on the head and neck of sun-exposed
skin. This fact has long suggested a role for sun exposure
in the tumorigenesis of AFX. UV radiation from sunlight
is an important risk factor for skin cancer [20]. UV-
induced p53 gene mutations occurring at dipyrimidine
sites have been demonstrated in AFX, suggesting a central
role for UV radiation in the pathogenesis of AFX [5,17].
p53 protein is a key regulator for cell-cycle arrest and
apoptosis induced by DNA damage [21]. Therefore Bax
and Gadd45 are the central downstream effectors of p53
[6]. It has been reported that low doses of UV-radiation
induced a rapid p53 accumulation followed by a decrease
which was correlated with a transient cell-cycle with-
drawal and presumably also DNA repair [22]. The associ-
ation between decreased DNA repair ability and AFX may
be supported by a report showing that patients with xero-
derma pigmentosum had AFX, and it is known that xero-
derma pigmentosum is related to DNA repair defects
[23,24]. On the other hand, high and sustained levels of
p53 were observed after a high dose of UV-radiation in
cells undergoing apoptosis [22]. Therefore, regulation of
p53 target genes was highly dependent upon the radiation
dose used, with high doses inducing only Bax and Gadd45
expression [22]. In the current study, it seemed that there
was a correlation between Bax and Gadd45 in these AFX
cases. These associations of Bax and Gadd45 noted in AFX
may be consistent with p53 effector upregulation against
UV radiation, although there seemed to be no correlation
between p53 expression, and the expression of Bax or
Gadd45.
Bax expression has been reported to be associated with
histological grade [25] and unfavorable prognosis [26] in
ovarian tumors. In the current study, Bax was expressed in
about 50% of the AFX cases. The frequency of Bax expres-
sion in AFX was significantly higher than that in BFH. This
difference suggests the essential difference between the
two lesions. Bax is a pro-PCD (programmed cell death)
protein and belongs to the Bcl-2 family [7]. As far as we
are concerned, there have been no reports presenting a
direct comparison between AFX and BFH in terms of
apoptotic behavior. However, it has been reported that
apoptotic behavior in AFX is as high as that in high-grade
sarcoma of MFH [27]. In addition, another research article
has reported that there is a significant difference between
MFH and BFH [28]. Therefore, it is reasonable to assume
that the apoptotic behavior of AFX is higher than that of
BFH. Moreover, the expression of Bax in AFX may reflect
apoptotic behavior.
We have previously reported the expression of Gadd45 in
a series of AFX, in which mutation of the Gadd45 gene
was not analyzed [16]. Gadd45 gene mutation is uncom-
mon in human tumors [13,14]. However, point muta-
tions were found at exon 4 of the Gadd45 gene in 13.6%
of pancreatic cancer cases, thereby suggesting that the pos-
sible dysfunction of Gadd45 plays a role in tumor devel-
opment in certain types of tumors [15]. In the current
study, no mutation of the Gadd45 gene at exon 4 was seen
in a series of AFX, regardless of the immunohistochemical
Atypical fibroxanthoma demonstrates the proliferation of  atypical spindle or polygonal cells arranged in fascicles, in a  haphazard or disorderly pattern Figure 1
Atypical fibroxanthoma demonstrates the prolifera-
tion of atypical spindle or polygonal cells arranged in 
fascicles, in a haphazard or disorderly pattern. (A). 
Atypical fibroxanthoma shows positive nuclear immunoreac-
tion for Bax (B). (H&E staining, A; × 180, Immunohistochem-
istry, B; × 200).
Table 2: Immunohistochemical features of atypical fibroxanthoma and benign fibrous histiocytoma
Lesion Bax Gadd45* Gadd45 mutation at exon 4 p53*
AFX 3/7 (43%)** 4/7 (57%) 0/6 (0%) 2/7 (29%)
BFH 0/7 (0%)** 1/7 (14%) NA 0/7 (0%)
AFX, atypical fibroxanthoma; BFH, benign fibrous histiocytoma (BFHs were selected at random from our histological files); *, data were reported 
previously; **, p < 0.05; NA, not assessed.BMC Dermatology 2009, 9:1 http://www.biomedcentral.com/1471-5945/9/1
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expression of Gadd45. This result may refute any possibil-
ity of dysfunction of Gadd45 in terms of gene mutation,
at least at exon 4 of the Gadd45 gene.
AFX untypically occurs outside the head and neck region,
such as in the extremities. The site-specific difference of
AFX between the head and neck region and other regions
is not well known. In the current series, 4 out of 7 cases
occured in the head and neck region, while 3 cases
occured in the extremities of the fingers and the leg. The
expression of Gadd45 in AFX was more frequent than that
in BFH, which was also true for the expression of Bax; BFH
rarely demonstrated Gadd45 or Bax expression. Bax
expression was seen in 1 out of 4 AFX cases in the head
and neck region (25%), but in 2 out of 3 AFX cases (67%)
in the extremities. On the other hand, Gadd45 expression
was seen in 2 out of 4 in the head and neck region (50%),
but in 2 out of 3 cases in the extremities (67%). It might
be possible that the expression of Bax or Gadd45 in AFX is
more prominent in the extremities, rather than in the
head and neck region. Namely, the expression of Bax or
Gadd45 in AFX may differ in a site-specific manner, pos-
sibly reflecting its pathogenesis. Further study will be
needed in order to characterize the site-specific difference
of AFX.
It remains controversial whether AFX and MFH are actu-
ally the same entity, or not. It seems that AFX and MFH
share histological and immunological features. A histio-
cytic/macrophage marker, CD68, is positive in more than
half of all AFX cases [29,30]. CD10 has been expressed in
almost all cases of MFH, as well as in cases of AFX [16,31].
However, the number of AFX cases with moderate/strong
or diffuse immunoreactivity for CD99 is significantly
larger than that of MFH cases [32]. Reduced immunoex-
pression for CD74 in AFX may be characterized compared
to that in MFH [33]. From a molecular aspect, AFX is char-
acterized by a diploid pattern, while the majority of chro-
mosomal changes in MFH are of an aneuploid pattern
[34,35]. H-, K-, and N-ras gene mutations are not present
in AFX, whereas MFH has H- and K-ras gene mutations,
although only a small number of cases was studied [36].
In contrast to MFH, AFX is strongly associated with UV
radiation in its pathogenesis. The formation of DNA pho-
toproducts by UV radiation has been reported to be
responsible for the development of skin cancer [37]. DNA
photoproducts can interfere with the binding of several
important cell-cycle regulatory and DNA damage-respon-
sive transcription factors [37]. It has been reported that
the accumulation of DNA photoproducts may play an
important role in the pathogenesis of AFX [17]. It is also
possible that AFX and MFH share the same pathway
which determines their morphology, but that AFX and
MFH may have different pathways of biological behavior
which determine their clinical behavior.
Conclusion
In the current study, we analyzed the immunohistochem-
ical expressions of the p53 effector proteins of Bax and
Gadd45 in AFX. Possible association between Bax and
Gadd45 without gene mutation at exon 4, was observed.
This result may refute any possibility of dysfunction of
Gadd45 in terms of gene mutation, at least at exon 4 of the
Gadd45 gene.
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